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OBJECTIVES The objective of this study was to compare the effectiveness and safety of adding dipyridamole
or aspirin to warfarin among patients with prosthetic heart valves using meta-analytic
techniques.
BACKGROUND Patients with prosthetic heart valves are at increased risk for valve thrombosis and arterial
thromboembolism. Oral anticoagulation alone, or the addition of antiplatelet drugs, has been
used to minimize this risk. An important issue is the effectiveness and safety of the latter
strategy.
METHODS A combined MEDLINE and manual search was made for relevant articles from 1966 to
November 1999. Standard meta-analysis techniques were used.
RESULTS Ten studies involving 2,199 subjects met the inclusion criteria. Compared with anticoagu-
lation alone, the addition of an antiplatelet agent reduced the risk of thromboembolic events
(odds ratio [OR]: 0.41, p , 0.001) and total mortality (OR: 0.49, p , 0.001). The risk of
major bleeding was increased when antiplatelet agents were added (OR: 1.50, p 5 0.033). For
major bleeding, the comparison of trials performed before and after 1990 (OR: 2.23 and 0.88,
respectively) showed that the chi-square test for heterogeneity was significant (p 5 0.025).
The latter trials used low-dose aspirin, suggesting that the risk of bleeding may be lower with
contemporary low-dose (100 mg daily) aspirin.
CONCLUSIONS Adding antiplatelet therapy, especially low-dose aspirin, to warfarin decreases the risk of
systemic embolism or death among patients with prosthetic heart valves. The risk of major
bleeding is slightly increased with antiplatelet therapy. Nonetheless, the risk of bleeding
appears to have diminished with the lower doses of aspirin used in the more recent trials,
resulting in a favorable risk-to-benefit profile. (J Am Coll Cardiol 2001;37:569–78) © 2001
by the American College of Cardiology
Patients with prosthetic heart valves are at increased risk for
both valve thrombosis and arterial thromboembolic events,
including stroke (1,2). Consequently, anticoagulation ther-
apy is used to lessen the thromboembolic risk, albeit at the
expense of increased anticoagulation-associated hemor-
rhage. Recently, several systematic reviews have attempted
to clarify the current best evidence for prosthetic valve
management (3,4). As such, current recommendations tend
to be very specific and are tailored to several clinical features,
including prosthetic valve location and type, presence of
atrial fibrillation and prior history of thromboembolism
(4,5). Unfortunately, the literature supporting these recom-
mendations is often difficult to interpret due to small
numbers of patients, lack of consistent control groups and
older studies with anticoagulation monitoring that predates
the International Normalized Ratio (INR).
As a means of improving the efficacy of antithrombotic
therapy after cardiac valve implantation, anticoagulation has
been augmented with an antiplatelet agent. Although the
results of some of the trials have been encouraging, showing
improved effectiveness with no substantial increase in bleed-
ing risk, the results are far from consistent (6–17). Previous
meta-analyses addressing the efficacy and safety of com-
bined antiplatelet and oral anticoagulant for prosthetic valve
management were potentially limited, having reviewed ei-
ther English language trials, published data (18,19) or trials
using dipyridamole (20) only.
We report a meta-analysis that includes data published in
abstract form and clinical trial reports in any language. The
goal of this study was to create a valid synthesis of all
available, methodologically sound data to further assess the
safety and efficacy of combined oral anticoagulant and
antiplatelet therapy versus anticoagulant monotherapy in
patients with prosthetic heart valves.
METHODS
Study identification. We used systematic methods to
identify all published randomized controlled trials (RCT)
comparing the addition of antiplatelet therapy with oral
anticoagulation in patients with prosthetic heart valves
(21–23). Our search strategy involved the MEDLINE
database using the search terms: heart-valve prosthesis,
mechanical heart-valve, thromboembolism, anticoagulant,
From the Department of Medicine, London Health Sciences Center, University of
Western Ontario, London, Ontario, Canada.
Manuscript received January 31, 2000; revised manuscript received September 6,
2000, accepted October 12, 2000.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(00)01135-9
antiplatelet and hemorrhage. The MEDLINE search was
augmented by manual searches of reference lists from the
individual reports, review articles, meta-analyses and con-
sensus statements. We included reports published as manu-
scripts or described in abstract form in any language from
January 1966 to November 1999.
Study eligibility. Studies were included in the meta-
analysis if: 1) patients with prosthetic heart valves were
enrolled, 2) there was a comparison of the addition of an
antiplatelet agent to oral anticoagulation, 3) treatment
groups were assigned through random allocation and 4)
objective methods were used to assess for the development
of major clinical outcomes or adverse consequences. Ab-
stracts were included. Study quality, apart from the above,
was not assessed. Reviewers were not blinded as to the
author, journal or type of publication.
Data extraction. Two reviewers independently extracted
data on three major outcomes: 1) rates of thromboembo-
lism, 2) major hemorrhagic complications and 3) total
mortality. The primary author’s definitions for the above
were accepted. In addition, the following data were ex-
tracted from each study: mean follow-up, target INR or
prothrombin time ratio, antiplatelet type and dose and
whether the study was single- or double-blinded. Prosthetic
valve type and position were not specifically reviewed
because the original publications did not consistently exam-
ine the outcomes using these variables.
Statistical analysis. All analyses were performed on the
intention-to-treat basis. The statistical method used has
been described in detail previously (24). A p value less than
0.05 (two-sided) was considered to be statistically signifi-
cant. A “typical” odds ratio (OR) along with 95% confidence
intervals (CI) were calculated for individual trials and for the
summary results.
Chi-square tests of heterogeneity were used to assess the
validity of combining trials. As these tests have low sensi-
tivity for detecting heterogeneity, a more liberal level of
statistical significance (p , 0.1) was assumed (25). If a test
of heterogeneity was significant, a random-effect analysis
was made and reported (26). In addition, for each outcome
measure we also used the fixed-effects approach of Mantel
Haenszel (27) and random-effects (26,28) models to esti-
mate summary treatment effects for all studies combined.
The number needed to treat to prevent one outcome event
(NNT), and the expected benefit per 1,000 patients treated
was estimated from fixed-effects models.
Sensitivity analyses. Sensitivity analyses were performed
on all three outcome events. The impact of the following
variables was assessed (predefined): studies published in
English versus other languages, abstract versus full publica-
tion, the type of antiplatelet agent used (aspirin versus
dipyridamole), whether the studies were double-blinded or
not and the type of model used (29), that is, whether fixed-
or random-effects.
Each study was deleted in turn to assess the impact of the
individual studies on the overall results. A cumulative
meta-analysis, based on chronological order, was performed
to assess the robustness of treatment effects over time
(30,31). To assess for the possibility of publication bias, we
estimated the number of “missing and negative” trials that
would have to exist and would nullify the results of the
meta-analysis according to the methods of Rosenthal and
L’Abbe (32,33).
RESULTS
Study characteristics. Our search strategy identified 10
prospective RCTs involving 2,199 subjects that met the
inclusion criteria (6–15). Study characteristics are listed in
Table 1. Previous meta-analyses asking a similar question
included only three (18) or four (19) of the English language
published trials or only those trials in which dipyridamole
(20) was used. Of the trials we identified, only three were
double-blinded (6,9,14). Two French language (10,13) and
one Japanese language (8) publications were identified. One
trial was published in abstract form only (11). A study by
Chesebro and colleagues (16) was identified but was ex-
cluded because it compared two treatment groups receiving
warfarin and either aspirin or dipyridamole and did not
include a treatment group randomized to no antiplatelet
therapy.
Of the trials included, six involved the antiplatelet agent
dipyridamole at daily doses of 400 mg (6,8), 225 mg to
400 mg (11), 375 mg (10,13) or up to 5 mg/kg (12). The
remaining four trials involved aspirin at doses of 500 mg
daily (7), 500 mg twice daily (9) and 100 mg daily (14,15).
Since they preceded the advent of the INR, earlier trials
reported ideal levels of anticoagulation as the following:
elevated prothrombin times at twice normal (6), 1.9 to 3.0
times normal (11), 1.8 to 2.3 times normal (7), 25% to 35%
greater than normal (10), Quick time 25% to 35% of control
(13), as thrombotest equivalents (10% of normal) (9) or
unspecified (12) Quick time or thrombotest equivalents.
The two trials published after 1990 reported a therapeutic
anticoagulation goal INR of 3.0 to 4.5 (14) and 2.5 to 3.5
(15).
Of the three main study outcomes, an arterial thrombo-
embolic event (TE) was well defined and was the primary
end point of all included trials. Definitions were similar and
involved either transient or permanent cerebral ischemic
injury or ultrasound or surgically confirmed other systemic
arterial embolism. Reported data for major hemorrhagic
Abbreviations and Acronyms
CI 5 confidence interval
INR 5 international normalized ratio
NNT 5 number needed to treat
RCT 5 randomized controlled trial
RRR 5 relative risk reduction
TE 5 thromboembolic events
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complications of anticoagulant therapy with or without
antiplatelet therapy were less consistent. Three original
publications provided no data on bleeding (8,11,12). Data
on bleeding for the Kasahara trial were abstracted from the
dipyridamole meta-analysis that included unpublished data
obtained from the registration file reviewed by the U.S.
Food and Drug Administration (20). Data from the Rajah
article was also available from the Pouleur meta-analysis but
excluded from ours because the denominator from the active
treatment groups was reported as 68 rather than 78 as in the
original abstract (rendering the results somewhat suspect).
The Meschengieser et al. (15) trial defined significant
bleeding as that causing death, requiring transfusion or
hospitalization. In the Turpie et al. (14) trial, major bleed-
ing was defined as overt hemorrhage associated with
$20 g/L drop in the hemoglobin level, the requirement for
transfusion of $2 units of blood or any intracranial, intraoc-
ular, intraarticular or retroperitoneal bleeding. Minor bleed-
ing constituted either epistaxis, genitourinary bleeding or
easy bruising. Two trials (7,9) did not distinguish between
major and minor bleeding events. For this analysis, any
intracerebral or gastroenteric bleeding event or episode of
hemoptysis was taken to represent a significant hemorrhage
in these two studies. One trial (6) reported only three
nonfatal gastrointestinal bleeding events that were pre-
sumed to be significant.
Mortality data were explicit for nine trials and not
provided in the original publication of the Kasahara trial (8);
this data was abstracted from the dipyridamole meta-
analysis (20) that included unpublished data (as above). One
trial provided clear data on mortality associated with hem-
orrhage and thromboembolism but did not provide data on
total deaths per treatment group (7).
Thromboembolic events. The results for the impact of
antiplatelet agents on the risk of TE events are summarized
in Table 2 and shown in Figure 1. Overall, antiplatelet
agents reduced the risk of TE events with an OR of 0.41
(95% CI: 0.29 to 0.58, p , 0.001). The heterogeneity
chi-square test was not significant (p 5 0.79). This treat-
ment effect corresponds to a relative risk reduction (RRR) of
57% (95% CI: 38% to 70%) and an NNT of 30 (95% CI: 19
to 62), both calculated using a fixed-effects model.
Trials were grouped according to study era (performed
pre-1990 or later) and the antiplatelet agent used (dipyr-
idamole or aspirin). The impact of antiplatelet agents was
consistent across time and with the available agents
(Table 3). None of the tests for heterogeneity were
statistically significant. A cumulative meta-analysis by
published date shows that the reduction in risk of TE was
Table 1. Characteristics of the Studies Included in the Meta-analysis
Study Ref Year Duration Drug INR n
TE Events Mortality Major Bleeding
Treated Control Treated Control Treated Control
Sullivan 6 1971 1 D 3.0–4.5 163 4/79 12/84 11/79 10/84 2/79 0/84
Altman 7 1976 2 A 1.8–2.3 122 3/57 13/65 1/57 2/65 5/57 3/65
Kasahara¶ 8 1977 2.5 D * 78 2/39 8/39 3/39 7/39 1/39 1/39
Dale 9 1977 1 A 2.0–2.2 148 2/75 10/73 3/75 6/73 13/75 5/73
PACTE 10 1978 1 D † 290 4/136 8/154 6/136 21/154 11/136 5/154
Rajah 11 1980 1–2 D 1.9–3.0 165 3/78 11/87 2/78 7/87 N/A N/A
Bran 12 1980 2 D ‡ 101 6/58 8/43 4/58 6/43 N/A N/A
Starkman 13 1982 2.5 D § 259 5/132 8/127 5/132 3/127 9/132 5/127
Turpie 14 1993 2.5 A 3.0–4.5 370 5/186 13/184 9/186 22/184 24/186 19/184
Meschengieser 15 1997 2 A 2.5–3.5 503 7/258 7/245 9/258 21/245 6/258 11/245
Totals 41/1,098 98/1,101 53/1,098 105/1,101 71/962 49/971
3.7% 8.9% 4.8% 9.5% 7.4% 5.0%
Annualized Rates 2.2% 5.3% 2.9% 5.8% 4.4% 3.0%
*Prothrombin time ratio 1.7; †prothrombin time ratio 1.3–1.6; ‡degree of anticoagulation not specified; §Quick time 25% to 35% of control; ¶includes data not published in
the original manuscript but included in an FDA submission (22).
A 5 aspirin; D 5 dipyridamole; Duration 5 mean duration of follow-up in years; INR 5 international normalized ratio; n 5 total study sample size; N/A 5 data not available;
Ref 5 reference; TE 5 thromboembolic events.
Table 2. Summary Results*
OR‡ 95% CI p Value
x2 Test of
Heterogeneity
p
Relative
Risk
Reduction*
Number
Needed to
Treat*†
Adjusted
Benefit per
1,000*
Thromboembolic events 0.41 0.29–0.58 , 0.001 0.79 57% 30 52
Mortality 0.49 0.35–0.67 , 0.001 0.49 49% 27 48
Major bleeding 1.50 1.03–2.18 0.033 0.26 — 68§ —
Major bleeding (excluding
Meschengieser)
1.81 1.21–2.71 0.0041 0.76 — 28§ —
*Derived from fixed-effects models; †number needed to treat to prevent one death; ‡a typical odds ratio less than 1.0 favors antiplatelet therapy; §number needed to harm; that
is, if you treat 68 or 28 patients, 1 will sustain a major bleed.
CI 5 confidence interval; OR 5 odds ratio.
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robust over time and was statistically significant after the
second trial. Although the magnitude of benefit dimin-
ished slightly over time, the results remained highly
statistically significant. The results were not influenced
by the meta-analysis technique used, whether a fixed- or
random-effects model; all were highly statistically signif-
icant. In general, the CIs around the estimated treatment
effect were slightly wider when using random-effects
models.
Mortality. Data on mortality were available for all 10 trials
and are shown in Table 2 and Figure 2. Total mortality was
reduced with antiplatelet agents with an OR of 0.49 (95%
CI: 0.35 to 0.67, p , 0.001). There was no evidence for
heterogeneity between studies. Both aspirin and dipyrida-
mole reduced mortality similarly. The overall effect on
mortality corresponds to an RRR of 49% (95% CI: 29% to
63%) and an NNT of 27 (95% CI: 18 to 55). The effect was
consistent across subgroups (Table 3, Fig. 2) and was not
influenced by the type of model used. A cumulative meta-
analysis showed that the magnitude of benefit was consis-
tent over time and was statistically significant after the fifth
trial.
Figure 1. Odds ratio plots (logarithmic scale) for thromboembolism according to whether assigned to antiplatetet therapy or control. The center of each
line represents the OR for the individual trials and subgroups with the ends of the horizontal line representing the 95% CIs. The solid line represents
an OR of 1; to the left of the line (OR , 1) favors antiplatelet therapy, and to the right of the line (OR . 1) favors control or placebo. The broken
line and the center of the box represent the pooled OR, and the ends of the horizontal line represent the pooled 95% CI. CI 5 confidence interval; OR 5
odds ratio.
Table 3. Subgroup Analyses
Trials*
Thromboembolic Events Mortality Major Bleeding†
OR‡ 95% CI p Value OR‡ 95% CI p Value OR‡ 95% CI p Value
Early DIP 0.42 0.26–0.67 , 0.001 0.56 0.36–0.87 0.0098 2.20 1.11–4.39 0.025
Early ASA 0.26 0.12–0.56 , 0.001 0.50 0.16–1.61 0.25 2.41 1.07–5.41 0.034
Heterogeneity x2 0.29 0.87 0.89
Pre-1990 0.37 0.25–0.55 , 0.001 0.55 0.36–0.83 0.0047 2.23§ 1.28–3.87 0.0044
Post-1990 0.58 0.29–1.17 0.13 0.40 0.24–0.67 , 0.001 0.88§ 0.37–2.13 0.78
Heterogeneity x2 0.28 0.35 0.025
All DIP 0.42 0.26–0.67 , 0.001 0.56 0.36–0.87 0.0098 2.20 1.11–4.39 0.025
All ASA 0.40 0.24–0.68 , 0.001 0.42 0.26–0.67 , 0.001 1.28 0.82–2.00 0.28
Heterogeneity x2 0.90 0.38 0.19
Early ASA 0.26 0.12–0.56 , 0.001 0.50 0.16–1.61 0.25 2.51§ 1.05–6.03 0.039
Later ASA 0.58 0.29–1.17 0.13 0.40 0.24–0.67 , 0.001 0.88§ 0.36–2.16 0.78
Heterogeneity x2 0.13 0.72 0.068
Double-blind 0.33 0.18–0.60 , 0.001 0.59 0.35–1.00 0.049 1.68 1.00–2.84 0.051
Not blinded 0.46 0.30–0.70 , 0.001 0.43 0.29–0.65 , 0.001 1.33 0.78–2.27 0.29
Heterogeneity x2 0.38 0.36 0.59
*Early refers to trials performed before 1990; later trials were performed after 1990, and all used aspirin; †When comparing early dypridamole, early ASA and later ASA studies
for the outcome of major bleeding, the x2 test for heterogeneity was less than the prespecified level of significance of ,0.10 (OR: 2.20, 2.41 and 0.98 respectively; p 5 0.081).
The x2 test for heterogeneity was not significant for the outcomes of thromboembolic events (p 5 0.31) or mortality (p 5 0.24); ‡a typical odds ratio less than 1.0 favors
antiplatelet therapy; §calculated using a random effects model as the test of heterogeneity was significant (p , 0.10) using the fixed effects model (28).
ASA 5 aspirin; CI 5 confidence interval; DIP 5 dipyridamole; OR 5 odds ratio.
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Major bleeding. Data on major bleeding (Table 2, Fig. 3)
were available for eight trials. There was an increase in the
risk of major bleeding when antiplatelet agents were added
to warfarin therapy with an OR of 1.50 (95% CI: 1.03 to
2.18; p 5 0.033). The test for heterogeneity was not
significant. However, the results of the analysis were influ-
enced by the type of model used. The results were conven-
tionally statistically significant when fixed-effects analyses
were made and of borderline significance using random-
effects models.
A cumulative meta-analysis (Fig. 4) showed that the risk
of major bleeding became statistically significant after the
third trial. Both the point estimate of bleeding risk and the
degree of statistical significance, however, appeared to
diminish over time and were markedly attenuated (OR from
1.81 to 1.50 and p 5 0.004 to p 5 0.033, respectively) with
Figure 2. Odds ratio plots (logarithmic scale) for total mortality according to whether assigned to antiplatetet therapy or control. The center of each line
represents the OR for the individual trials and subgroups with the ends of the horizontal line representing the 95% CIs. The solid line represents an OR
of 1; to the left of the line (OR , 1) favors antiplatelet therapy, and to the right of the line (OR . 1) favors control or placebo. The broken line and
the center of the box represent the pooled OR, and the ends of the horizontal line represent the pooled 95% CI. CI 5 confidence interval; OR 5 odds
ratio.
Figure 3. Odds ratio plots (logarithmic scale) for major bleeding according to whether assigned to antiplatetet therapy or control. Data for major bleeding
was available for only eight of the trials. The center of each line represents the OR for the individual trials and subgroups with the ends of the horizontal
line representing the 95% CI. The solid line represents an OR of 1; to the left of the line (OR , 1) favors antiplatelet therapy, and to the right of the
line (OR . 1) favors control or placebo. Statistically significant tests of heterogeneity comparing pre- and post-1990 and early and late aspirin trials are
shown. The broken line and the center of the box represent the pooled OR, and the ends of the horizontal line represent the pooled 95% CI. CI 5
confidence interval; OR 5 odds ratio.
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the addition of the Meschengeiser et al. (15) trial. The latter
trial was a comparison of high-dose warfarin versus the
combination of low-dose aspirin and warfarin, and the risk
of bleeding was not different between the two groups.
Excluding this trial and repeating the analysis provided
stronger evidence that the risk of bleeding was increased
with antiplatelet therapy with an OR of 1.81 (95% CI: 1.21
to 2.71, p 5 0.004, fixed-effects model) and 1.76 (95% CI:
1.16 to 67, p 5 0.008, random-effects model).
We explored the impact of each individual trial by
excluding each in turn. Excluding one aspirin trial (9) or two
dipyridamole trials (10,13) rendered the risk of bleeding
conventionally nonsignificant. Unpublished data on bleed-
ing from the Kasahara trial were used in a previous meta-
analysis (20) and included in ours. Repeating the analysis
with this data excluded did not alter the results. The
inclusion of the unpublished bleeding data from the Rajah
trial (20) did influence the results. The absolute number of
events for each group (four treated, seven control) were
included in a sensitivity analysis. Inclusion of this small
number of events lowered the OR from 1.50 to 1.39 and
raised the p value from 0.033 to 0.066. Similarly, when
viewing the dipyridamole trials alone, inclusion of this data
lowered the OR from 2.20 to 1.63 and raised the p value
from 0.025 to 0.11. Therefore, although the statistical test
of heterogeneity was not significant (possibly as a result of
low statistical power), there appeared to be clinical differ-
ences in the risk of bleeding between trials.
The risk of major bleeding did not differ between trials
using dipyridamole and aspirin (p 5 0.19). Nonetheless, the
risk of bleeding was higher in studies performed before 1990
as compared with the two more recent trials (OR: 2.23 vs.
0.88, p 5 0.025) (14,15). The tests for heterogeneity
comparing the two later aspirin trials with either the early
aspirin or the early dipyridamole trials were statistically
significant (p 5 0.068 and 0.066, respectively), again
suggesting that the risk of bleeding was less in the two most
recent aspirin studies. When the above subgroup analyses
were repeated with the Meschengieser et al. (15) trial
excluded, there was less of an impact of pre-1990 versus
post-1990 trials (OR: 2.29 vs. 1.28, p 5 0.17), dipyridamole
versus all aspirin trials (OR: 2.20 vs. 1.63, p 5 0.49) or early
and later aspirin trials (OR: 2.41 vs. 1.28, p 5 0.23).
Additional sensitivity analyses and publication bias.
There were no differences for any of the end points among
trials published in English as compared with other lan-
guages, whether published as an abstract or as a manuscript
or if double-blind methodology was used or not. The
Kasahara study (8) was published in Japanese and only
partial data were available; the analyses were repeated with
this article excluded, and the results were unchanged. As a
result, the addition of unpublished data (used in a previous
meta-analysis [20]) did not alter the results apart from the
inclusion of the Rajah unpublished data as described above.
There was no impact on the end points of TE or death
when each of the other trials was also excluded in turn.
Next, a series of hypothetical variances and observed
minus expected mortalities (O to E), according to the
method of Peto (24) were modeled for the Kasahara trial.
This showed that 25 excess deaths in the antiplatelet group
as compared with the controls would have had to occur to
render the overall results of the meta-analysis conventionally
statistically nonsignificant. The failure to report such a
massive treatment-induced mortality excess was considered
highly unlikely. Moreover, unpublished mortality data from
the Kasahara study, which was included in the dipyridamole
meta-analysis (20), showed that mortality was nonsignifi-
cantly reduced with dipyridamole. The possibility of publi-
Figure 4. Cumulative meta-analysis of OR plots (logarithmic scale) for major bleeding according to whether assigned to antiplatelet therapy or control. The
center of each line represents the OR for the cumulative trials with the ends of the horizontal line representing the 95% confidence interval. The solid
line represents an OR of 1; to the left of the line (OR , 1) favors antiplatelet therapy, and to the right of the line (OR . 1) favors control or placebo.
p values are provided for the accumulated trials once conventional statistical significance (p , 0.05) was achieved. OR 5 odds ratio.
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cation bias was assessed by the methods of L’Abbe and
Rosenthal (32,33). According to the method suggested by
L’Abbe, it can be shown that more than 80 small negative
trials (40 per group) or 11 larger negative trials (event rate
10%, 250 per group) would have to exist to nullify the
results (32). Using the method of Rosenthal (33), it was
estimated that 30 to 50 negative trials would have to exist in
order to nullify the results of the meta-analysis for the
outcomes of death and thromboembolic events, respectively.
DISCUSSION
The main conclusion of our meta-analysis is that the
addition of an antiplatelet agent (primarily low-dose aspirin
but also higher dose aspirin and dipyridamole) to warfarin in
patients with prosthetic heart valves reduces the risk of
death and systemic thromboembolic events. Our analysis
showed that dipyridamole and aspirin seemed to reduce the
risks of death and thromboembolism similarly. However,
the risk of major bleeding appeared to be increased with the
early dipyridamole trials as compared with the later aspirin
trials where the aspirin dosage was lower, and only 100 mg
daily was administered. As such, our results are in accord
with the Fifth ACCP Consensus Conference on Anti-
thrombotic Therapy where it is stated: “in view of the
advantageous effects of low-dose aspirin in combination
with oral anticoagulants, the indications for use of dipyrid-
amole require further investigation” (5).
Chesebro and colleagues (16) performed a randomized
trial comparing warfarin and dipyridamole (400 mg daily) to
warfarin and aspirin (500 mg daily) in patients with a pros-
thetic heart valve replacement. The risk of TE was slightly
lower, but not statistically significant, among those allocated
dipyridamole (0.5 vs. 1.8 per 100 patient-years). Bleeding rates
were higher among those receiving concomitant aspirin as
compared with dipyridamole (6.6 vs. 1.6 per 100 patient-years,
p , 0.001). These results are discordant with ours and may
reflect the dose of aspirin chosen; 500 mg in the Chesebro
study (16) as compared with the lower risk of bleeding when
100 mg daily doses of aspirin (14,15) were used.
Aspirin effective but at less bleeding risk. The relative
effectiveness and safety of aspirin may reflect patient selec-
tion, the degree of anticoagulation (target INR) sought or
the dose of aspirin used. In the comparison of the aspirin
trials, the risk of bleeding in the trials performed before
1990 (7,9) (that is, before the advent of widespread use of
the standardized INR) was higher even though the target
INR sought in the early trials was lower compared with the
post-1990 trials (14,15) (Table 1). It is our postulate that
the lower risk of bleeding in the more recent trials reflects
the use of lower dose aspirin: 100 mg daily in the two
contemporary trials compared with 500 to 1,000 mg daily in
the earlier aspirin trials. Efficacy, on the other hand, did not
appear to be dependent upon the degree of anticoagulation
or dose of aspirin. In this regard, a more detailed discussion
of some of the two later individual trials is in order.
In the Turpie et al. double-blind randomized controlled
trial (14), 186 patients were assigned to aspirin (100 mg/day
delayed release, enteric coated) plus warfarin, and 184 were
assigned to placebo plus warfarin. Patients were included if
they had a mechanical prosthetic valve or tissue valves and
atrial fibrillation or a history of thromboembolism. The
target INR was 3.0 to 4.5. The primary end point (major
embolism or death) was reduced among those assigned to
aspirin (1.9% vs. 8.5% per year, p , 0.001). The stroke rate
(1.3% vs. 4.2% per year, p 5 0.027) and overall mortality
(2.8% vs. 7.4%, p 5 0.01) was reduced with aspirin.
Furthermore, a composite outcome that could reflect net
clinical benefit (major systemic embolism, nonfatal intracranial
hemorrhage, death due to hemorrhage and vascular deaths)
was also reduced with aspirin (3.9% per year vs. 9.9% per year,
p 5 0.005). Although the risk of bleeding was increased with
aspirin, this was primarily due to minor bleeding including
bruising, epistaxis and hematuria. Importantly, the risk of
major hemorrhagic events did not differ significantly between
groups (8.5% aspirin vs. 6.6% placebo, p 5 0.43).
In the Meschengieser et al. trial (15), patients were
randomized to either a high target INR (3.5 to 4.5; mean
achieved 3.98) or a lower target INR (2.5 to 3.5; mean
achieved 3.11) plus 100 mg of aspirin daily. The primary
outcome events were rates of thromboembolism and bleed-
ing. The rates of thromboembolism were similar at 2.8%
and 2.7%, respectively. The risk of major bleeding (4.5%
warfarin alone vs. 2.3% warfarin plus aspirin) and minor
bleeding (17% warfarin alone vs. 14% warfarin plus aspirin)
did not differ between groups but tended to favor the
combination of low-dose aspirin and a lower target level of
anticoagulation. Three intracranial hemorrhages occurred in
the warfarin alone arm; none were seen in the combination
arm. Therefore, the addition of low-dose aspirin with a
lower level of anticoagulation was as effective, and possibly
safer, as compared with a higher level of anticoagulation.
These results are consistent with the randomized trial by
Altman et al. (17) who compared the effect of a low (INR
2.0 to 3.0) or high (INR 3.0 to 4.3) degree of anticoagula-
tion in combination with dipyridamole (150 mg/day) and
aspirin (660 mg/day) in patients with heart valve replace-
ment. The rates of TE were similar between the low and
high INR groups (1.92 vs. 4.94 per 100 patient-years,
respectively) although there were very few events overall.
The risk of bleeding, however, was less with the lower target
INR (3.8 vs. 24.7 per 100 patient-years, p , 0.02). They
concluded that a lower INR (2,3) used conjointly with
platelet inhibitors was effective and safer than a higher
target INR (17).
Improvements over previous meta-analyses. The first
overview comparing rates of valve thrombosis, major embo-
lism and bleeding was unable to show an advantage of the
combination of aspirin and anticoagulation over anticoagu-
lation alone; bleeding risk was increased, however (3). The
studies included in the overview were not comparative
randomized trials.
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The meta-analyses performed by Fiore and colleagues
(18) and Cappelleri and colleagues (19) were subject to bias
through inclusion of English language only trials published
as full manuscripts. The Fiore meta-analysis, published in
abstract form only, included four trials comparing the use of
aspirin as an adjunct to oral anticoagulation. The Cappelleri
meta-analysis included five trials: four involving aspirin and
one involving dipyridamole. Moreover, the study by Chese-
bro and colleagues (16) was included in both these meta-
analyses but was excluded from ours, as patients treated with
warfarin were only randomized to receive either aspirin or
dipyridamole. Although a control group receiving warfarin
alone was subsequently included in the analysis, patients
were not randomized to warfarin alone or warfarin and
either of the two antiplatelet regimens (16).
The Pouleur et al. (20) meta-analysis comprised trials of
dipyridamole only. It also included previously unpublished
data, updated from the original publications, and a submis-
sion to the U.S. Federal Drug Agency. For the end points of
TE and death, the results of our meta-analysis are in accord
with theirs, and sensitivity analyses show that inclusion or
exclusion of the unpublished data from published trials does
not materially change our results or conclusions. The one
discrepancy is for the end point of bleeding. Our meta-
analysis suggests bleeding risk is increased with dipyrida-
mole but theirs does not (OR: 2.2 vs. 1.001, respectively).
The test of heterogeneity between the analyses is conven-
tionally statistically significant (chi-square 3.968, p 5
0.046). This may reflect our emphasis on major bleeding,
whereas they included data on hemorrhagic events, whether
fatal or not (20). The differences may also reflect the use of
unpublished data. In this regard it is interesting to note that
the bleeding risks for two of the studies (6,10) were
qualitatively different in the Pouleur meta-analysis as com-
pared with the original publications. In both original stud-
ies, the bleeding risk was slightly higher with dipyridamole;
in the data used in the meta-analysis, the bleeding risk was
lower. As such, our results may represent a more conserva-
tive estimate of bleeding risk.
In comparison with the above, our meta-analysis is more
powerful, including data on 2,199 subjects from 10 trials
and less subject to bias through inclusion of trials of any
language, use of dipyridamole or aspirin and including
publications as a manuscript or abstract. Furthermore, the
robustness of our conclusions are reinforced through exten-
sive sensitivity analyses which, among other things, included
the impact of unpublished data, English language and other
language publications (34) and whether double-blind meth-
odology was used. None of these methodological factors
impacted on our estimate of the effectiveness and safety of
adjunctive antiplatelet therapy.
Potential limitations. Our analysis was not adjusted for
study quality and, therefore, potentially at risk for this bias.
A recent study found that the use of summary scores to
identify trials of high methodological quality was problem-
atic (35). Notwithstanding, it has also been shown that
incorporation of studies of low methodological quality tend
to show an increased estimate of benefit (36). However, our
sensitivity analyses did not detect any effect of exclusion of
individual trials (some of which were of lesser quality, for
example the Rajah study [11], published as an abstract only)
or a difference among double-blinded trials on the rates of
thromboembolism or death prevention. We did not use
blinded techniques during study selection or data abstrac-
tion as such procedures have not been found to be necessary
(37). The possibility of publication bias in medical research
is important but difficult to eliminate when performing a
meta-analysis (23,38). To the present, unpublished data in
meta-analyses remains controversial but should not be
systematically excluded (39). Our analysis included all pub-
lished data from the included randomized trials as well as
some unpublished data obtained for an FDA submission
and used in a previous meta-analysis (20). We were unable
to verify this unpublished data. However, sensitivity analy-
ses, excluding the unpublished data, did not alter our
conclusions, except for the risk of major bleeding, as
previously discussed.
We included trials that claimed to have used proper
randomization techniques but did not seek to authenticate
the veracity of these claims (40). Furthermore, although
improper concealment of treatment allocation has been
shown to be an important source of bias in RCTs (and
therefore in meta-analyses based upon them), none of the
included trials provided adequate information on this (41).
Finally, although our study involved data on almost 2,200
subjects and the results for thromboembolism and death are
highly statistically significant, there is the possibility of a
type II error given the marginal degree of significance for
the outcome of major bleeding. It can be shown that an
individual trial of almost 3,200 subjects would be necessary
to show a difference in the rate of bleeding from 5.0% to
7.4%, assuming a two-tailed alpha of 0.05 and 80% power.
Pogue and Yusuf (42) have suggested that the sample size
required for a meta-analysis should be at least as large as a
single optimally powered RCT. As such, our analysis may
be underpowered with respect to that end point only.
Clinical implications. Our results suggest that low-dose
aspirin could be safely added to anticoagulation with an
acceptable risk of bleeding and with the expectation that
rates of death and thromboembolism would be reduced.
Indeed, it is quite possible that outcomes would be im-
proved with a more widespread use of aspirin as compared
with existing guidelines (see Appendix). A survey performed
by Ray and Turpie showed that low-dose aspirin was
underused by North American cardiac surgeons. Only 21%
of respondents routinely used aspirin in conjunction with
anticoagulants (43). The two most common reasons for not
using aspirin were the perceived increase in bleeding risk
(49% of nonusers) or lack of proven benefit (23% of
nonusers) (43). These concerns are unfounded and not in
accord with the available trial and meta-analytic evidence.
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APPENDIX
CURRENT RECOMMENDATIONS FOR ADDING ASPIRIN
TO COUMADIN IN PATIENTS WITH PROSTHETIC
HEART VALVES
According to the Fifth ACCP Consensus Conference on
Antithrombotic Therapy (5), it is recommended that the
addition of low-dose aspirin should be considered among:
1) patients with a mechanical valve who suffer a TE despite
adequate anticoagulation;
2) those with caged ball or caged disk valve (INR target 3.0,
range 2.5 to 3.5);
3) patients with mechanical valves and additional risk
factors (INR target 3.0, range 2.5 to 3.5). The risk
factors include: prior thromboembolism, atrial fibrilla-
tion, coronary heart disease, large left atrium, left atrial
thrombus, ball valve, more than one mechanical pros-
thetic valve or a mechanical prosthetic valve in the mitral
position;
4) a lower level of anticoagulation (INR 2.5, range 2.0 to
3.0) along with low-dose aspirin rather than a target
INR of 3.0 in patients with tilting disk or bileaflet
mechanical valves in the mitral position or bileaflet
mechanical valves in the aortic position plus atrial
fibrillation.
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